D
espite repeated attempts, no large trial of medical therapy for heart failure with preserved ejection fraction (HFpEF) has met its primary end point. Two entangled challenges have contributed to this impasse: uncertainty in the pathophysiology and heterogeneity of the patient population. The dominant theory of HFpEF pathophysiology has been impaired cardiac relaxation, 1 but it now competes with several rivals. [2] [3] [4] [5] [6] The inconvenient reality may be that no single mechanism accounts for symptoms in all patients. Splitting the umbrella diagnosis of HFpEF into mechanismbased subtypes would facilitate the identification, testing, and ultimately personalization of novel therapies. 7 Exercise intolerance is a cardinal symptom of HFpEF, one whose distinct etiologies could be the basis of a disease taxonomy. A useful system for organizing these etiologies springs from 1 central relationship, the dependence of exercise performance on oxygen (O 2 ) consumption. 8 Exercise capacity can be formally defined as the rate of O 2 consumption (Vo . 2 ) at peak exercise. Any factor that limits peak Vo . 2 , by impeding O 2 delivery or utilization, can be said to cause exercise intolerance. O 2 delivery and utilization are in turn determined by a series of steps akin to a bucket brigade that transport O 2 from the mouth all the way to respiring mitochondria. The main steps in this O 2 cascade include alveolar ventilation, diffusion from alveolar gas into pulmonary capillary blood and loading onto hemoglobin, convective transport by the heart (cardiac output) and vasculature to the peripheral microcirculation, diffusion into skeletal muscle, and mitochondrial respiration: in aggregate, the O 2 pathway (Figure 1) . 9 The cause of exercise intolerance in HFpEF has been classically attributed to a defect in 1 step, cardiac output, 1, 10 but the growing recognition of extracardiac abnormalities 6, 11, 12 underscores the need to characterize the entire O 2 pathway. Many O 2 pathway steps can be quantified by using invasively monitored cardiopulmonary exercise testing. Once quantified, a patient's mechanism of exercise intolerance can be discretized into a list of defective steps, eg, impaired cardiac output and anemia. This list of causal O 2 pathway defects personalizes a diagnosis of exercise intolerance much as a genotype of tumor driver mutations personalizes a diagnosis of cancer.
Expressing exercise intolerance in terms of O 2 pathway defects is not only valuable for diagnosis, but also
Clinical Perspective
What Is New?
• Systematic quantification of the oxygen transport and utilization cascade (O 2 pathway) revealed extensive variation in the mechanisms of exercise intolerance among patients with heart failure with preserved ejection fraction.
• Impaired skeletal muscle diffusion capacity was found to be an important peripheral cause of exercise intolerance.
• The vast majority of patients harbored compound mechanisms of exercise intolerance, defined as ≥2 defective steps in the O 2 pathway.
• The predicted improvement in exercise capacity attributable to correcting any single O 2 pathway defect was constrained by interactions with comorbid defects.
What Are the Clinical Implications?
• The importance of impaired peripheral O 2 extraction to exercise intolerance in heart failure with preserved ejection fraction highlights the need to develop widely applicable tools for diagnosing peripheral abnormalities during exercise.
• A taxonomy of heart failure with preserved ejection fraction should account for the diversity of underlying mechanisms of disease.
• The efficacy of treating any individual O 2 pathway step such as cardiac output will depend on a patient's comorbid O 2 pathway abnormalities. raises the prospect of targeting them for therapy. A defect's appeal as a target, however, depends on the magnitude of its causal impact on exercise capacity. This impact can be quantified as the improvement in peak Vo . 2 that would result from fully correcting the defect. For example, discovering that a patient's cardiac output is depressed invites the question, just how much would the patient's exercise capacity improve if cardiac output were restored? The ability to answer this question could prove vital to the success of cardiac output therapies, but few tools exist to address it. The central challenge is that the answer could be highly context-dependent. If depressed cardiac output were the patient's only O 2 pathway defect, then the outcome of treating it would be self-evident: fully restoring cardiac output should fully correct exercise capacity. If, however, cardiac output were one of several O 2 pathway defects, interactions between them could impede the Vo . 2 response to cardiac output therapy. Two patients with precisely the same cardiac output defect, but distinct sets of accessory O 2 pathway defects, could experience very different responses to therapy. This differential sensitivity to therapy caused by O 2 pathway background would be analogous to the variable penetrance of a pathological gene mutation caused by genetic background.
Here we sought to quantify the steps of O 2 transport from mouth to mitochondria, at the highest resolution to date in HFpEF. We also sought to quantify, for the first time, the relative importance of each of a patient's causal defects. Achieving these goals could enable new taxonomies of HFpEF as well as new paradigms for personalizing therapy. Finally, peak Vo . 2 is a potent predictor of survival in HFpEF, 13 further highlighting the value of systematically quantifying its determinants.
METHODS

Patients
Our study population was drawn from consecutive patients referred to the Massachusetts General Hospital from 2006 to 2016 for chronic New York Heart Association II to IV symptoms, who underwent cardiopulmonary exercise testing with invasive hemodynamic monitoring. Patients with HFpEF were identified from this retrospective series by the following criteria: (1) chronic New York Heart Association II to IV symptoms; (2) an explicit cutoff for reduced exercise capacity, namely peak Vo . 2 ≤80% of predicted on the basis of age, sex, and height 14 ; (3) preserved left ventricular ejection fraction, ≥0.50; and (4) a hemodynamic criterion for heart failure, 15, 16 namely a pulmonary arterial wedge pressure ≥15 mm Hg at rest while supine, or alternatively a peak exercise pulmonary arterial wedge pressure ≥25 mm Hg. Individuals from the same referral series were assigned to the control group if they demonstrated normal exercise capacity, peak Vo . 2 ≥90% of predicted, and objective evidence of normal cardiovascular function by multiple measures: (1) left ventricular ejection fraction ≥0.50, and (2) supine resting pulmonary arterial wedge pressure <15 mm Hg. There was partial overlap between the patients with HFpEF studied here and those from our prior study (24/79 patients). 6 Patients were excluded from analysis if they met any of the following criteria: (1) incomplete pulmonary arterial catheter measurements, (2) submaximal exercise as evidenced by peak respiratory exchange ratio <1.0, (3) age <40 years, (4) documented intracardiac shunting, (5) severe valvular heart disease, (6) flow-limiting coronary artery disease, and (7) arterial O 2 saturation <90% at peak exercise. This study was approved by the Partners Healthcare Institutional Review Board, and all patients gave informed consent. The authors had full access to the data and take responsibility for its integrity and for the article as written.
Cardiopulmonary Exercise Testing
All patients performed maximal incremental upright cycle ergometry with a pulmonary arterial catheter placed in the internal jugular vein and a systemic arterial catheter placed in the radial artery. Left ventricular ejection fraction was assessed either by resting echocardiography or resting ventriculography. Further testing details are described in the Methods in the online-only Data Supplement.
O 2 Pathway Analysis
Six steps of the O 2 pathway were quantified at peak exercise ( Figure 1 (Table I and Algorithm 1 in the online-only Data Supplement). To estimate a patient's O 2 pathway parameters from these equations, peak exercise measurements were used as inputs, and the parameters were solved for as outputs.
To predict the impact of modulating an O 2 pathway parameter (eg, cardiac output) on Vo . 2 , the above procedure was run in reverse (Algorithm 2). The values of a patient's O 2 pathway parameters were specified as inputs and the patient's peak exercise responses, in particular, peak Vo . 2 , were solved for as outputs. Thus, an abnormal parameter such as cardiac output could be set to a normal reference value ( Figure I in the onlineonly Data Supplement), and the expected improvement in a patient's peak Vo 
RESULTS
Patients with HFpEF (n=79) and controls (n=55) were of comparable age, sex, and body mass index (Table) . Exercise capacity, defined as peak Vo . 2 , was reduced by 34±2% (P<0.001) in HFpEF relative to controls. We partitioned the O 2 pathway steps that explain this Vo 
Diagnosing O 2 Pathway Causes of Exercise Intolerance
O 2 Delivery
Total O 2 delivered to the periphery, defined as the product of cardiac output and arterial O 2 content at peak exercise, was reduced by 31±0.3% (P<0.001) in HFpEF compared with controls. This impairment was caused by a 27±3% (P<0.001) reduction in cardiac output and a 5±2% (P=0.02) reduction in hemoglobin concentration. Patients with HFpEF also harbored a 36±3% (P<0.001) reduction in alveolar ventilation and a 31±3% (P<0.001) reduction in lung diffusion capacity at peak exercise.
O 2 Extraction
Total O 2 extracted by the periphery, defined as the difference between arterial and venous O 2 content (ΔAVo 2 ) at peak exercise, was reduced by 8±2% (P=0.01) in HFpEF compared with controls. ΔAVo 2 has frequently been used as a metric of the periphery's ability to extract O 2 6,10,19-22 because it integrates the effects of multiple O 2 pathway steps. However, its value also depends on factors external to the periphery. 23 In particular, because of the competition between convective and diffusive transport of O 2 , ΔAVo 2 depends on muscle blood flow and therefore cardiac output.
To evaluate the drawbacks of using ΔAVo 2 to gauge O 2 extraction by the periphery, we quantified the sensitivity of both ΔAVo 2 and Vo . 2 to changes in cardiac output (Q) for a representative patient with HFpEF ( Figure 2A , Algorithm 3). By explicitly accounting for the antagonism Figure 2B displays the expected value of ΔAVo 2 at each value of Q for the control population (Algorithm 4). This locus of values serves as a calibration curve, indicating normal ΔAVo 2 at each possible value of Q. By comparing observed HFpEF ΔAVo 2 with the calibration curve value at observed HFpEF Q, we found that ΔAVo 2 was 26±2% (P<0.001) lower than predicted had O 2 extraction in HFpEF been normal ( Figure 2B ).
Using the ΔAVo 2 calibration curve, we went on to reinterpret ΔAVo 2 values reported in prior studies, 10, [19] [20] [21] [22] including those that had concluded that peripheral O 2 extraction in HFpEF was normal. We found that all 5 studies, each from a distinct laboratory, reported ΔAVo 2 values that fell short of normal ΔAVo 2 when controlled for Q ( Figure 2C ). We obtained similar results after repeating this analysis with ΔAVo 2 calibration curves derived from study-specific control populations ( Figure II in the online-only Data Supplement). Thus controlling ΔAVo 2 for Q led to unanimous agreement between prior studies that O 2 extraction in HFpEF was impaired.
To identify the O 2 pathway step that impairs peripheral extraction in HFpEF, we calculated each patient's skeletal muscle diffusion capacity (D M ). Mean D M was 36±2% (P<0.001) lower in patients with HFpEF than in controls ( Figure 2D and 2E) .
Impaired diffusion-mediated O 2 transport is a plausible mechanism of abnormal O 2 extraction in heart failure, 24 but impaired mitochondrial respiration could also contribute. We estimated that mitochondrial capacity for O 2 utilization (v max ) was reduced by 27±3% (P<0.001) in HFpEF relative to controls (Methods in the online-only Data Supplement). We conducted a sensitivity analysis to assess the degree to which our conclusions about D M were influenced by our mitochondrial parameter estimates. 17 
Compound Mechanisms
After assessing each patient's full complement of O 2 pathway defects, we counted how often a defect occurred in isolation versus in concert with other defects. We termed the former "simple" mechanisms of exercise intolerance ( Figure 3A ) and the latter "compound" mechanisms. Strikingly, 97% of our patients with HFpEF harbored a compound mechanism ( Figure 3B ), with ≥2 defects in the O 2 pathway (<80% of the reference value).
Ranking O 2 Pathway Causes of Exercise Intolerance
We next used O 2 pathway analysis to gauge the functional significance of each of a patient's O 2 pathway defects. To rank defects by their causal impact on exercise capacity, we derived a novel property of the physiology, the VO2 deficit recovery (VDR) coefficient. The VDR coefficient for a given O 2 pathway defect is the normalized improvement in a patient's peak Vo . 2 that would be expected from correcting the defect, while holding all other O 2 pathway parameters fixed.
We found that normalizing cardiac output would be predicted to improve the Vo 2 =Q·ΔAVo 2 ), but this approach assumes that ΔAVo 2 would be unaffected by the rise in Q. When we calculated VDR Q under this faulty assumption, the result overestimated deficit recovery by a factor of 10.
Of all the O 2 pathway defects in HFpEF, normalizing skeletal muscle diffusion capacity led to the largest predicted recovery of the Vo tions ( Figure IIIB in the online-only Data Supplement). Finally, we also compared the impact of D M and Q on exercise capacity by using a distinct metric, the Vo 
Context Dependence: The Influence of Comorbid Defects
We next examined factors that influence the magnitude of an O 2 pathway defect's impact on Vo (Hb), denoted VDR Dm(Q,Hb,Va,Dl) . Upon correction of multiple defects in the O 2 pathway background, we found that mean VDR Dm(Q,Hb, Va,Dl) jumped to 60% of the initial Vo . 2 deficit, >2-fold higher than VDR Dm ( Figure 4B , bar 4, blue segment). Turning to the context dependence of VDR Q , we found that first normalizing the O 2 -loading system (Hb, V A , D L ) subsequently tripled the impact of correcting Q, mean VDR Q(Hb,Va,Dl) =24% ( Figure 4B, bar 4 , red segment). These results demonstrate the dramatic role that background deficits could play in determining the efficacy of therapy.
After exploring the effects of context averaged over all patients with HFpEF, we examined its implications at the individual level. By plotting a patient's O 2 pathway defect versus its corresponding VDR coefficient, we discovered unanticipated heterogeneity among patients with the same-size defect ( Figure 4C and 4D ). Another surprising trend emerged from individual level data: the maximum VDR of an O 2 pathway defect diminished as the defect became more severe (Figure 4C and 4D) . One might expect that correcting a severe defect would substantially benefit Vo . 2 . However, we found that individuals with 1 severe defect often harbored a high burden of comorbid O 2 pathway defects ( Figure V in the online-only Data Supplement; Figure 3B ). The VDR trend thus expresses the tyranny of comorbidities: as a patient's burden of O 2 pathway defects grows, the benefit of treating any one in isolation fades.
DISCUSSION
By reasoning about the pathophysiology of HFpEF from exercise data, we attempted to shed light on key clinical dilemmas in the field: How important is the periphery's contribution to exercise intolerance? How heterogeneous is HFpEF and why? What makes exercise intolerance so hard to treat? Answering these questions rested on 2 main tasks: diagnosing the causes of a patient's exercise intolerance and ranking their functional significance. First, we sought to deconstruct the pathophysiology of exercise intolerance by expressing it in terms of the component steps of O 2 transport and utilization (O 2 pathway). Cataloging each patient's O 2 pathway defects revealed a peripheral mechanism of disease previously uncharacterized in HFpEF, impaired skeletal muscle diffusion capacity. It also revealed extensive patient heterogeneity. HFpEF is classically regarded as a cardiac disorder, but we found that every O 2 pathway step was defective in 1 or more patients. What's more, this heterogeneity did not fit a tidy pattern of 1 defect per patient ( Figure 3A) . Most patients harbored a combination of defects ( Figure 3B ). The complex structure of this heterogeneity is at the heart of what makes exercise intolerance in HFpEF difficult to diagnose and treat. In the second phase of our analysis, we sought to quantify the impact of each O 2 pathway defect on a patient's exercise capacity. These properties of the physiology simultaneously inform personalized therapy (which defect has the largest impact?) and disease subtyping (which patients share a dominant defect?). To calculate these properties, we developed a novel tool, the VDR coefficient, which quantifies the causal impact of 1 O 2 pathway defect while accounting for the influence of comorbid defects. We found that even when a defect was large (eg, cardiac output), the predicted benefit of correcting it could be modest, because comorbid defects would hold Vo . 2 recovery in check. The O 2 pathway step with the largest impact on exercise capacity was located in the periphery, skeletal muscle diffusion.
What limits exercise capacity in HFpEF? We chose to distill the mechanisms of disease down to elemental causes such as the O 2 pathway defects. Previous studies have associated HFpEF with pathologies such as left ventricular hypertrophy and vascular stiffness, or comorbidities such as aging, obesity, hypertension, and diabetes mellitus. 3 The mechanisms by which these factors influence exercise intolerance should be largely expressible in terms of O 2 pathway defects. Connecting the dots from upstream mechanisms to O 2 pathway defects will be an important direction of future research.
Here we reported the first systematic analysis of the O 2 pathway in HFpEF, but our findings for a subset of O 2 pathway steps are corroborated by prior studies. For example, similar reductions in Vo . 2 and cardiac output at peak exercise have been widely reported in HFpEF. 10, 21 Abnormalities of skeletal muscle 25 and pulmonary function, 26 including a comparable reduction in peak lung diffusion capacity, 12 have also been reported, although relatively underappreciated. Recently, the contribution of peripheral O 2 extraction, as measured by ΔAVo 2 , to exercise intolerance has received greater attention. However, despite close interstudy agreement regarding the absolute value of ΔAVo 2 in HFpEF (when measured invasively, Figure 2C) , 6, 10, 21 the role of the periphery remains unsettled.
The Periphery's Contribution to Exercise Intolerance
Opinions regarding the causal significance of the periphery in HFpEF are divided, but they can be reconciled by analyzing O 2 extraction in terms of its component O 2 pathway steps. At the heart of the discord lies an insidious misconception, that the periphery's ability to extract O 2 can be gauged by the total O 2 actually ex-ORIGINAL RESEARCH ARTICLE tracted (ΔAVo 2 ). Using ΔAVo 2 as a metric of O 2 extraction, studies that reported similar values in HFpEF and controls concluded that peripheral abnormalities cannot explain exercise intolerance. 10, 21 Studies that reported a reduction in HFpEF ΔAVo 2 relative to controls concluded that the periphery cannot be ignored. 6, 19, 20 To resolve this dilemma, we first note that a conventional cardiopulmonary exercise testing analysis leans heavily on the Fick equation to dissect exercise capacity: Vo . 2 =Q·ΔAVo 2 . This equation invites the mistaken impression that cardiac output (Q) and ΔAVo 2 are independent of each other. Although ΔAVo 2 integrates the effects of multiple noncardiac O 2 pathway steps, its value depends on the heart as well: the faster an O 2 -carrying red blood cell races through a capillary, the less time O 2 has to diffuse into muscle mitochondria, which leaves more O 2 unextracted and, in turn, raises venous O 2 content. Consequently, if at peak exercise Q were to rise further-all else being equal-ΔAVo 2 would fall due to decreased time available for diffusion. 27, 28 Conversely, if Q were to fall, ΔAVo 2 would rise (Figure 2A) . Confusion in the field has arisen because ΔAVo 2 in isolation has been used to gauge the performance of the periphery, overlooking its dependence on Q. To untangle the two, we had to explicitly account for the O 2 pathway steps that drive peripheral extraction, including diffusion and mitochondrial respiration, together with their relationship to Q. By unpacking the ΔAVo 2 term in this way, we showed that when prior studies were reinterpreted to account for impaired Q, they all reported ΔAVo 2 values in HFpEF that were inappropriately low ( Figure 2C) . O 2 pathway analysis thus unifies the evidence that the peripheral response to exercise in HFpEF is impaired.
What causes impaired peripheral extraction? We identified impaired skeletal muscle diffusion capacity as a novel defect in HFpEF. O 2 moves from the muscle microcirculation to the mitochondria by diffusion. This process depends on both muscle capillarity and muscle fiber size, which together determine the diffusion capacity for O 2 . 29 Our data cannot identify the specific pathology that accounts for reduced diffusion capacity, but the work of others has shown that capillary to fiber ratios are reduced in HFpEF. 25 
Patient Heterogeneity
Is HFpEF one disease or many? 30, 31 If it is many diseases, then this heterogeneity could itself span a spectrum of complexity. At one extreme, HFpEF could be a structured set of 1-problem disorders (simple mechanisms), wherein each patient harbors a single defect in the O 2 pathway. Such patients would fall neatly into disease subtypes, one for each O 2 pathway step ( Figure 3A) . At the opposite extreme, HFpEF could be a loose collection of multiproblem disorders. Indeed, we found that nearly every patient harbored a compound mechanism of exercise intolerance, each with his or her own personal profile of defects ( Figure 3B ). In addition to muddying the taxonomy of HFpEF, compound mechanisms raise hard questions about treatment: When a patient's exercise intolerance has multiple causes, how significant is each one's contribution to symptoms?
Clinical Implications
To address questions germane to therapy and diagnosis, we shifted our focus from quantifying the O 2 pathway defects to quantifying their causal impact on exercise capacity. We cast the problem of personalizing therapy as deciding which of a patient's O 2 pathway defects has the largest causal impact and thus the greatest therapeutic potential. We found that the magnitude of a defect's impact on Vo . 2 depended not only on the defect itself but also on a patient's entire array of comorbid defects. In a patient with 1 lone defect (simple mechanism), the magnitude of its causal impact on Vo . 2 can be stated trivially: it accounts for 100% of the Vo . 2 deficit. But in HFpEF, our data suggest that simple mechanisms are the exception and compound mechanisms the rule. When multiple O 2 pathway defects coexist, quantifying causal effects is no longer straightforward. Defects interact. From the viewpoint of the heart, these interactions may drastically alter the relationship between cardiac output and exercise capacity. Consequently, the magnitude of cardiac output's impact on Vo .
2 is a system property-it depends on all comorbid O 2 pathway defects and cannot be judged by the size of the cardiac output defect alone. Accounting for comorbid defects, we showed that in HFpEF, the predicted impact of normalizing cardiac output on the Vo . 2 deficit is modest, an average improvement of 7%. The notion that comorbidities herald a difficult disease course is familiar to clinicians of all stripes. For exercise intolerance in HFpEF, O 2 pathway analysis shows how this notion can be granted causal, quantitative precision.
Why are patients with HFpEF so hard to treat? The system properties of their exercise pathophysiology offer a compelling explanation: the benefit of correcting any single O 2 pathway defect would be reined in by comorbid defects. Cardiac output is particularly susceptible to such interactions, because its augmentation comes at the cost of diffusive O 2 transport in both the lungs and skeletal muscle. These processes are impaired in HFpEF 12 (Table) and may help explain why cardiocentric therapies have not been successful to date. Current and future trials of cardiac output therapies, eg, rateadaptive atrial pacing, will further test these concepts. Exercise end points such as peak Vo . 2 and actigraphy metrics 32 would be particularly valuable in such trials, because cardiac end points in isolation could paint an incomplete picture of therapeutic efficacy. In contrast, peak Vo . 2 integrates the entire O 2 pathway, explaining its potent prognostic value in heart failure.
The system properties of the O 2 pathway clarify another key observation in HFpEF, the efficacy of exercise training. 33 Exercise training is capable of boosting multiple O 2 pathway steps, including skeletal muscle diffusion capacity, 34 lung diffusion capacity, 35 mitochondrial respiration capacity, 36 and cardiac output 37 ; in HFpEF, specifically, these effects have been shown to manifest as enhanced ΔAVo 2 . 22, 38 Thus, even though the benefits of exercise on symptoms may not come as a great surprise, O 2 pathway analysis provides a causal, quantitative basis for its unique salutary effects.
The same analysis we used to inform the personalization of therapy, diagnosing and ranking O 2 pathway defects, can also be applied to disease subtyping. Heterogeneity within our HFpEF cohort reflects each patient's individual profile of O 2 pathway defects. Because a central aim of diagnosis is to link symptoms to their cause, this heterogeneity presents a challenge for HFpEF nosology. One solution would be to first characterize a patient's O 2 pathway defects through exercise testing and then assign him or her to a subgroup of patients with shared defects, eg, "HFpEF-Q". Such a diagnostic label would answer the question: What's abnormal (Figure 5A) ? The relevance of this scheme to therapy may be limited, however, because 2 individuals could have the same Q defect, but radically different responses to Q therapy ( Figure 4E and 4F) . Caution is therefore warranted if patients are to be grouped together by virtue of a common O 2 pathway defect, a seemingly natural criterion for defining a subtype of disease or for including patients in a clinical trial. Perhaps a HFpEF taxonomy should group patients with shared susceptibilities to therapy. The diagnostic label could then reflect shared causal impact of an O 2 pathway defect, HFpEF-VDR Q , answering the question: What should we treat ( Figure 5B) ? The VDR coefficients are patient-centric measures of a defect's causal impact and thus natural metrics by which to gauge patient similarity for disease subtyping.
To estimate a patient's O 2 pathway defects and their functional impact, we used exercise testing with invasive monitoring. Although not routine clinical practice, this approach is increasingly common and, in some cases, guideline-recommended to aid in the diagnosis of HFpEF. 39 Advances in noninvasive techniques for measuring cardiac output, blood gas levels, 40 and skeletal muscle properties could facilitate the widespread use of O 2 pathway analysis. This study highlights the rationale and unmet need for such a systematic analysis of a patient's pathophysiology-in particular, the role of the periphery.
Study Limitations
Our patients with HFpEF were selected from a referral population and differed from clinical trial populations [41] [42] [43] A B 
ORIGINAL RESEARCH ARTICLE
in several respects. They were younger, were more predominantly male, and exhibited lower rates of diabetes mellitus and hypertension. When we recalculated key results in patients >60 years of age and stratified by sex, we observed similar Q and D M defects and similar values of VDR Q and VDR Dm (Table II in the online-only Data  Supplement) . However, a strength of our study was the use of characteristic symptoms together with invasive hemodynamic measurements when defining HFpEF. Furthermore, our patients did share important similarities with trial populations, including comparable peak Vo . 2 and hemodynamic measurements (Table) , echocardiographic parameters (66% with left atrial enlargement), and heart failure hospitalization rates (18% per year).
Peak volitional effort is critical to implicating O 2 pathway steps as causes of exercise intolerance. To maximize the likelihood that peak effort was achieved, we excluded patients in whom respiratory exchange ratio did not reach 1.0, and we noted that peak respiratory exchange ratio was nearly identical between HFpEF and controls (mean respiratory exchange ratio of 1.16 versus 1.17 in HFpEF versus controls and interquartile range, 1.1-1.2 in both groups).
We used mixed venous O 2 levels to estimate muscle diffusion capacity. Although the majority of venous return emerges from the femoral veins during cycle ergometry, more refined estimates of D M could be made with local (femoral) measurements of blood flow and O 2 levels (Methods in the online-only Data Supplement). Furthermore, the degree of mismatch between blood flow and metabolism within muscle will also be important to determine. 44, 45 To estimate the impact of manipulating an O 2 pathway defect, we based our analysis on the causal physical principles that underlie the physiology. One limitation of our approach is that we did not account for possible biological adaptations, namely that modulating 1 O 2 pathway step could, over time, trigger changes in other steps. That said, all our Vo 
Conclusions
Overcoming the treatment impasse in HFpEF hinges on an improved understanding of disease pathophysiology. Exercise intolerance is a heterogeneous, difficult-to-treat symptom, because a typical patient harbors a compound mechanism of disease, with a unique profile of O 2 pathway defects, each of which exerts a context-sensitive and rarely dominant influence on exercise capacity. Personalized measures of causal influence such as the VDR coefficients could be used to stratify patients for clinical trials and for diagnostic purposes to tailor therapy. Finally, the system properties of the physiology favor therapies that influence multiple O 2 pathway steps simultaneously, in particular, exercise training.
